Kevin Sayer - DexCom CEO and President and Director

DXCM -- USA Stock  

Quarterly Earning Report: November 6, 2019  

  CEO
Mr. Kevin R. Sayer serves as Chairman of the Board, President, Chief Executive Officer of DexCom Inc. He has served on our Board since November 2007, as our President since June 2011 and as our Chairman of the Board since July 2018. From January 2013 until January 2015, Mr. Sayer also served as our Chief Operating Officer. In connection with Mr. Gregg assuming a new role as Executive Chairman of the Board of Directors, Mr. Sayer assumed the role of Chief Executive Officer effective on January 1, 2015. From April 2007 to December 2010, Mr. Sayer served as Chief Financial Officer of Biosensors International Group, Ltd., a medical technology company developing, manufacturing and commercializing medical devices used in interventional cardiology and critical care procedures. Prior to joining Biosensors, from May 2005 to April 2007, Mr. Sayer served as an independent healthcare and medical technology industry consultant. From March 2004 to May 2005, Mr. Sayer was Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., a company offering clinical reference laboratory services. From August 2002 to March 2004, Mr. Sayer worked as an independent healthcare and medical technology industry consultant. Mr. Sayer served as Chief Financial Officer of MiniMed, Inc. from May 1994 until it was acquired by Medtronic, Inc. in August 2001. Mr. Sayer served as Vice President and General Manager of Medtronic MiniMed after the acquisition until August 2002
Age: 60  CEO Since 2018      
858-200-0200  http://www.dexcom.com
Sayer is a Certified Public Accountant and received his Master Degree in Accounting and Information Systems concurrently with a B.A., both from Brigham Young University. As CEO, Mr. Sayer has direct responsibility for our strategy and operations..

Kevin Sayer Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (0.01) % which means that it has lost $0.01 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.01 % meaning that it created $0.01 on every $100 dollars invested by stockholders.
The company currently holds 1.1 B in liabilities with Debt to Equity (D/E) ratio of 159.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. DexCom has Current Ratio of 5.93 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 9 records

CEO Since

Gary HuffLaboratory Corporation Of Ameri
2017
Christopher LinthwaiteFluidigm Corporation
2016
Helmy EltoukhyGuardant Health
2017
James BoyleLaboratory Corporation Of Ameri
N/A
Deborah TannerLaboratory Corporation Of Ameri
2015
John RatliffLaboratory Corporation Of Ameri
2016
Gajus WorthingtonFluidigm Corporation
2016
Michael McMullenAgilent Technologies
2015
Stephen LinthwaiteFluidigm Corporation
2016

Entity Summary

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DexCom operates under Diagnostics Research classification in USA and is traded on BATS Exchange. It employs 2800 people.DexCom (DXCM) is traded on BATS Exchange in USA. It is located in 6340 Sequence Drive and employs 2,800 people. DexCom is listed under Medical Equipment category by Fama And French industry classification.

DexCom Leadership Team

Kevin Sun, Interim CFO
Eric Topol, Independent Director
Nicholas Augustinos, Independent Director
Lanny Roper, CFO, Vice President
Patrick Murphy, Chief Compliance Officer, Vice President General Counsel
Mark Foletta, Independent Director
Jonathan Lord, Independent Chairman of the Board
Jeffrey Moy, Senior Vice President - Operations
Donald Abbey, Executive Vice President Quality and Information Technology
Jay Skyler, Independent Director
Jake Leach, Senior Vice President of Research and Development
Jorge Valdes, Chief Technical Officer and Executive VP
Kevin Sayer, CEO and President and Director
Heather Ace, Senior Vice President Human Resources
Terrance Gregg, Executive Chairman
John Lister, Senior Vice President General Counsel
Richard Doubleday, Senior Vice President - Worldwide Sales and Marketing
Jess Roper, CFO and Sr. VP
Richard Collins, Independent Director
Barbara Kahn, Independent Director
Steven Pacelli, Executive VP of Strategy and Corporate Devel.
Andrew Balo, Senior Vice President - Clinical and Regulatory Affairs
Steven Altman, Independent Director
Quentin Blackford, CFO

Stock Performance Indicators

Current Sentiment - DXCM

DexCom Investor Sentiment

Most of Macroaxis users are currently bullish on DexCom. What is your opinion about investing in DexCom? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

DexCom Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for DexCom and Agilent Technologies. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.
Search macroaxis.com